Phase 4 N=25 Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery
Intraocular Lens Associated Postoperative Inflammation
Primary: The Change in Intraocular Pressure (IOP) From Baseline
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Renal Cell Carcinoma
Primary: The Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest — 0 Participants
N/A N=4,299 An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Insulin-Related Treatment Change From Initial Insulin Therapy — 2171 Participants
Phase 4 N=6 Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients
Heart Failure · Sleep Apnea Syndromes
Primary: Reduction in Episodic Oxygen Desaturation
Phase 2 N=78 A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
Agitation and Aggression in Alzheimer's Disease
Primary: Treatment Emergent Adverse Events (TEAEs) — 53 Participants
Phase 3 N=1,304 A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
Depressive Disorder, Major
Primary: Time to First Relapse During the First 52 Weeks of the Double-Blind Treatment Period — 232; 225; 336 Days — p=0.5305
Phase 1 N=120 Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Endometrial Adenocarcinomas · Neuroendocrine Tumors · Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Primary: Maximum Tolerated Dose (MTD) — 50; 50; 5.0; 5.0 DOX mg/m2 PM01183 mg FD
N/A N=57 Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer
Head and Neck Neoplasms
Primary: Number of Participants With Grade ≥2 Radiation Dermatitis at 50 Gy (Per Protocol Set) — 3; 9; 6; 18 Participants
N/A N=37 Meditation in Veterans With PTSD and Mild TBI
Stress Disorders, Post-Traumatic · Concussion, Mild
Primary: Clinician-Administered PTSD Scale (CAPS5)
N/A N=158 Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles
Diabetes
Primary: Injection Site Pain for BD Nano PRO Needle Compared to Each of Three (3) Commercially Available Comparators — 17.55; 17.39; 9.13 mm
Phase 1 N=77 Relative Bioavailability Study of Emodepside IR-tablets and Solution
Filariasis
Primary: PK (AUC0-7d) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution. — 1215; 852; 931; 674 h.ng/ml
Phase 3 N=35 Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers
Healthy Volunteers
Primary: Cohort 1: Area Under the Concentration-time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t) of M3 Metabolite — 117.518; 163.615 h*pg/mL
Phase 1 N=28 A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve (AUC0-t) of Entrectinib and M5 Metabolite — 18500; 16600; 3610; 3070 nmol*h/L
Phase 3 N=43 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Primary: Efficacy Endpoint: Responder Rate at End of Study — 32 Participants — p=<0.0001
Phase 3 N=558 Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
Type 1 Diabetes
Primary: Change in HbA1c From Baseline to 24 Weeks — 0.14; 0.11 percent